- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01943253
Water-jet Assisted ESD vs Conventional ESD Technique for Treating Early Gastric Cancer
Water-jet Assisted Endoscopic Submucosal Dissection (ESD) in Comparison to Conventional ESD Technique for Treatment of Early Gastric Cancer
- Introduction The aim of the study is to evaluate the efficacy and safety of ESD by use of a new water-jet assisted ESD system using the HybridKnife® in patients with early gastric neoplastic lesions in comparison to the conventional ESD established in Japan. The water-assisted ESD technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions as well as coagulation of bleeding can be performed with the same device without need for changing the instrument. These options should accelerate the procedure and may increase its safety and efficacy.
- Hypothesis The water-jet assisted ESD technique using the HybridKnife® bears the advantage of less instrument changes due to the combination of high-frequency cutting and water-jet application in one single instrument. This should lead to a simplified ESD procedure, shorter learn-ing curve and especially to a shorter procedure time.
The water-jet assisted ESD technique should be shorter than the conventional ESD techniques using IT2-, Dual- and Hook-Knifes at least with the same safety and effectiveness.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Düsseldorf, Germany
- Evangelisches Krankenhaus Düsseldorf
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults (≥ 18 years) with confirmed diagnosis of gastric adenoma or early gastric adenocarcinoma
- differentiated mucosal adenocarinoma without ulcer findings ≤ 60 mm in diameter.
- Lesions with ulceration ≤ 30 mm in diameter.
- undifferentiated type of mucosal cancer is ≤ 20 mm.
- The patient has given written informed consent.
Exclusion Criteria:
- pregnancy
- coagulopathy (INR>2.0, platelets < 70/nl)
- mucosal lesions which did not meet the inclusion criteria
- evidence of local or distant metastases according to endoscopic ultrasound (EUS) and/or CT scan, EUS (7.5 MHz probe) findings of tumor infiltration into deep layers of the submucosa or muscularis propria. -Patients unfit for deep sedation by use of propofol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Conventional ESD
Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4)
RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
|
Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4)
RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
|
|
Active Comparator: Hybridknife ESD
Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) |
Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4)
RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Procedure time
Time Frame: during procedure
|
The primary objective of the study is the procedure time of ESD using the conventional ESD technique in comparison to the water-jet assisted HybridKnife®-ESD technique.
|
during procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
en bloc resection rate
Time Frame: in procedure
|
Resection of the targeted lesion including coagulation markers in one piece.
|
in procedure
|
|
histological R0 rate
Time Frame: 7 days after procedure
|
En-bloc resection and histological confirmation of horizontal and vertical free margins of neoplasia.
|
7 days after procedure
|
|
Histologically incomplete resection
Time Frame: 7 days after procedure
|
Tumor infiltrated (R1) or undetermined (RX) margins of the resected specimen.
|
7 days after procedure
|
|
procedure related morbidity and mortality and complication rate
Time Frame: 30 days after procedure
|
procedure related morbidity and mortality
|
30 days after procedure
|
|
complication rate
Time Frame: 30 days after procedure
|
any complication occurs after procedure within 30 days, such as bleeding or perforation rates
|
30 days after procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Horst Neuhaus, Evangelisches Krankenhaus Düsseldorf
- Principal Investigator: Pinghong Zhou, Endoscopy Center, Zhongshan Hospital, Fudan University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hybrid ESD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasms
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongRecruiting
-
National Cancer Center, KoreaUnknownSubmucosal Tumor of StomachKorea, Republic of
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Chinese University of Hong KongRecruiting
-
Universitätsklinikum Hamburg-EppendorfOvesco Endoscopy AGSuspendedSubmucosal Tumor of StomachGermany
-
Fujian Medical UniversityEnrolling by invitation
-
Fudan UniversityActive, not recruitingGastric (Stomach) CancerChina
-
Asan Medical CenterRecruitingStomach Neoplasm | Gastric (Stomach) CancerKorea, Republic of
Clinical Trials on Conventional ESD
-
Shandong UniversityRecruitingEarly Gastric Cancer | Endoscopic Submucosal Dissection | Robot SurgeryChina
-
Shandong UniversityNot yet recruitingColorectal Neoplasms | Robot Surgery | Endoscopic Submucosal Dissection (ESD)China
-
Asan Medical CenterUnknownColorectal NeoplasmsKorea, Republic of
-
Istituto Clinico HumanitasCompleted
-
Kaiyun LiuNot yet recruitingColorectal Lesions | Endoscopic Submucosal Dissection (ESD) | FASTER Robot
-
University of Roma La SapienzaCampus Bio-Medico UniversityCompletedColorectal Neoplasia | Colorectal Superficial Neoplasia | Colorectal Precancerous LesionsItaly
-
Second Affiliated Hospital, School of Medicine,...CompletedTo Compare the Efficacy and Safety of Hybrid ESD and ESD in the Treatment of Colorectal LSTChina
-
Chinese University of Hong KongRecruitingSuperficial Esophageal, Gastric or Colorectal LesionsHong Kong
-
Taihe HospitalNot yet recruiting
-
Carol Davila University of Medicine and PharmacyRecruitingNeoplasm, Colorectal | Neoplasm, Stomach | Neoplasm, Esophagus | Neoplasm, DuodenalRomania